The matrix vesicle cargo miR-125b accumulates in the bone matrix, inhibiting bone resorption in mice by Minamizaki, Tomoko et al.
ARTICLE
The matrix vesicle cargo miR-125b accumulates in
the bone matrix, inhibiting bone resorption in mice
Tomoko Minamizaki1, Yuko Nakao1,2, Yasumasa Irie1,3, Faisal Ahmed1, Shota Itoh1,2, Nushrat Sarmin1,
Hirotaka Yoshioka 1,8, Asako Nobukiyo4, Chise Fujimoto1, Shumpei Niida5, Yusuke Sotomaru4,
Kotaro Tanimoto2, Katsuyuki Kozai3, Toshie Sugiyama6, Edith Bonnelye7, Yuichiro Takei 1,9 & Yuji Yoshiko1*
Communication between osteoblasts and osteoclasts plays a key role in bone metabolism.
We describe here an unexpected role for matrix vesicles (MVs), which bud from bone-
forming osteoblasts and have a well-established role in initiation of bone mineralization, in
osteoclastogenesis. We show that the MV cargo miR-125b accumulates in the bone matrix,
with increased accumulation in transgenic (Tg) mice overexpressing miR-125b in osteoblasts.
Bone formation and osteoblasts in Tg mice are normal, but the number of bone-resorbing
osteoclasts is reduced, leading to higher trabecular bone mass. miR-125b in the bone matrix
targets and degrades Prdm1, a transcriptional repressor of anti-osteoclastogenic factors, in
osteoclast precursors. Overexpressing miR-125b in osteoblasts abrogates bone loss in dif-
ferent mouse models. Our results show that the MV cargo miR-125b is a regulatory element
of osteoblast-osteoclast communication, and that bone matrix provides extracellular storage
of miR-125b that is functionally active in bone resorption.
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Cell-to-cell communication is pivotal for all multicellularorganisms. Most cell types exchange information throughsoluble factors or direct interaction, but they also release
extracellular vesicles (EVs) that can have an impact on neigh-
boring or distant cells. The biological significance of EVs has been
affirmed in numerous studies on intercellular communication
that document the transfer of proteins, lipids, and nucleic acids;
of these, microRNAs (miRNAs) have drawn much attention as
EV cargos1,2. miRNAs, ~22 nucleotides in length, constitute a
class of non-coding RNAs and induce gene silencing by binding
to target sites within the 3′UTR of targeted mRNAs, resulting in
suppressing protein synthesis and/or mRNA degradation3. miR-
NAs have been shown to be involved in a wide range of biological
processes such as cell cycle control4, developmental processes5,
glucose homeostasis6, immune responses7, bone metabolism8,
and so on.
In general, EVs are released into the extracellular fluids;
however, matrix vesicles (MVs) budding from polarized mature
osteoblasts accumulate in the unmineralized bone matrix
(osteoid). MVs in the osteoid initiate calcium and phosphate
crystal formation inside vesicles by utilizing the calcium channels,
phosphate transporters, and enzyme activities required in calcium
and phosphate transport and initial mineral formation. Calcium
phosphate crystals thereafter grow, penetrate the lipid bilayer of
MVs, and expand to mineralize bone matrix9. Advances in global
analysis indicate that MVs share certain features in common with
EVs10,11, including the presence of miRNAs12 and of numerous
proteins (see http://bioinf.xmu.edu.cn/MVsCarta/), some of
which are known regulators of osteoclast and osteoblast devel-
opment (e.g., TNFRSF11B13, WNT5A14, SEMA4D15), but whe-
ther they are functionally active when carried as cargo is not yet
known. We therefore tested the hypothesis that MVs play an
important, previously undefined role in osteoclasts and osteo-
blasts beyond their known involvement in bone matrix miner-
alization. We report here that miR-125b is a MV cargo that
accumulates in bone matrix where it inhibits osteoclastogenesis
and bone resorption via downregulation of the transcriptional
repressor PRDM1.
Results
MVs inhibit osteoclast formation in vitro. To address possible
novel bone biological functions of MVs, we isolated MVs from
the extracellular matrix (ECM) deposited by mouse osteoblastic
MC3T3-E1 cells. The isolated vesicles fulfilled the expected
morphological and biochemical criteria of MVs9 (Supplementary
Fig. 1a–d). Treatment of mouse bone marrow macrophage
(BMM) cultures with isolated MVs in the presence of CSF1 (M-
CSF) and TNFSF11 (RANKL)16–18 decreased formation of
tartrate-resistant acid phosphatase (TRAP)-positive multi-
nucleated cells (MNCs, i.e., osteoclasts) (Fig. 1a); no osteoclasts
formed with or without MVs in the absence of RANKL (Fig. 1a).
Consistent with the histochemical results, treatment with MVs
also decreased the expression of osteoclast marker genes Nfatc1, a
transcription factor necessary for osteoclastogenesis18, Dcstamp19
and Ctsk20 (Fig. 1b) as well as resorption pit formation21 (Fig. 1c).
Similar effects were observed in the mouse macrophage cell line,
RAW-D (Supplementary Fig. 2a, b) with RANKL, in which an
accompanying uptake of dye from labeled MVs to cells was also
evident (Supplementary Fig. 2c). Treatment with MVs from rat
and human primary osteoblast cultures (Supplementary Fig. 2d,
e) confirmed the presence of anti-osteoclastogenic factor(s) in
MVs across species. The RANKL-decoy receptor TNFRSF11B
(osteoprotegerin (OPG)), which inhibits osteoclastogenesis13,22,
has been reported in MVs in the conditioned medium of vascular
smooth muscle cells (http://bioinf.xmu.edu.cn/MVsCarta/).
Contrary to smooth muscle cells, we did not detect OPG in our
osteoblast-derived MVs (Supplementary Fig. 1c), suggesting that
MVs inhibit osteoclast formation independently of the RANKL-
OPG pathway. Although dye transfer occurred from labeled MVs
to MC3T3-E1 cells (Supplementary Fig. 3a), MVs did not elicit
significant effects on osteogenic differentiation and bone-like
nodule formation in these (Supplementary Fig. 3b) or rat primary
osteoblast (Supplementary Fig. 3c) cultures. The data suggest that
MVs modulate osteoclastogenesis but not osteoblastogenesis
in vitro.
miR-125b mimics the MV effects in vitro. Recently PCR array
profiling has identified miRNAs in MVs isolated from rat
chondrocyte cultures12. We therefore used miRNA microarray
analysis of osteoblastic (MC3T3-E1) MVs and identified 176
miRNAs (GSE140242 at NCBI GEO), 76 of which were common
between mouse and human (Supplementary Data 2), with several
good candidates for regulators of genes involved in osteoclast
formation23–27 (Supplementary Table 1). Of these, miR-125b was
more abundant in MVs than in the parent MC3T3-E1 cells from
which they derived (Fig. 1d), primary human and rat osteoblasts
(Fig. 1e) and RAW-D cells cultured with or without RANKL
(Fig. 1f). Notably, however, treatment with MVs increased miR-
125b levels in RAW-D cells (Fig. 1g). We then established a
subclone of MC3T3-E1 cells with lower levels of miR-125b
(Supplementary Fig. 4a) but normal osteogenic capacity (E1low)
(Supplementary Fig. 4b) to do a loss-of-function study. MVs from
E1low cells had no significant effect on TRAP+ MNC formation
in RAW-D cells (Supplementary Fig. 4c). Meanwhile, transfection
of miR-125b mimic (Fig. 1g) had higher efficacy than those with
control miRNA against TRAP+ MNC formation (Fig. 1h) and
associated gene expression (Nfatc1, Dcstamp, and Catsk) (Fig. 1i).
miR-125b mimic (Supplementary Fig. 4d) did not affect osteo-
genesis in MC3T3-E1 or the mouse mesenchymal stem cell line
ST2 models (Supplementary Fig. 4e, f). These data indicate that
miR-125b participates in the inhibitory effect of MVs on osteo-
clastogenesis in vitro.
Transgenic mice have high bone mass and fewer osteoclasts. To
determine whether miR-125b as MV cargo plays a functional role
in bone in vivo, we generated transgenic (Tg) mouse lines (#5, #7,
and #16; Supplementary Fig. 5a) expressing mmu-miR-125b-5p
in osteoblasts by using human osteocalcin promoter27 (Fig. 2a, b).
Mice (males) of the three lines at 9- and 12-weeks of age exhibited
identical phenotypes including high bone mass (Supplementary
Fig. 5b); line #5 was used for further analyses. Figure 2b shows
cell- and tissue-specific expression of miR-125b in Tg mice, which
were born at normal Mendelian ratios and grew normally (Sup-
plementary Fig. 5c). Tg femurs (12-week-old males) and verteb-
rae (L3 of 10-week-old females) exhibited higher bone mass than
their corresponding wild-type (WT) mice (Fig. 2c), due to
increased trabecular bone (12-week-old females, Fig. 2d); histo-
logical assessment of Tg tibiae (9- and 10-week-old female mice)
also confirmed this event (Supplementary Fig. 6a–c). WT and Tg
mice displayed equal numbers of alkaline phosphatase (ALP)-
positive osteoblasts (Fig. 2e) and equal mineral apposition rates
(MARs; calcein double-labeling) (Fig. 2f), indicating that bone
formation was not affected by miR-125b overexpression in
osteoblasts. However, the percentage of TRAP+ cell surface per
trabecular bone surface was lower in Tg compared to WT mice
(Fig. 2g). No difference in TRAP staining was seen in the zone of
calcified cartilage and subchondral bone (Fig. 2h), which may
reflect lower accumulation of miR-125b in bone at the chondro-
osseous junction in Tg mice.
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miR-125b targets Prdm1 in osteoclast precursors. To identify
the mechanisms underlying MV-mediated impaired osteoclasto-
genesis, we analyzed Tg and WT bone and bone marrow popu-
lations ex vivo. No difference was observed in bone formation
between Tg and WT bone marrow stromal cell cultures (Fig. 3a)
or between Tg and WT calvaria cell cultures (Supplementary
Fig. 7a). Similarly, no difference was seen between Tg and WT
cellular and MV ALP activity (Supplementary Fig. 7b) or their
ALPL and ANXA5 levels (Supplementary Fig. 7c). However,
higher levels of miR-125b were present in Tg vs. WT MVs
(Supplementary Fig. 7d) and in Tg vs. WT bone matrix (Fig. 3b).
Given that miR-125b was not detected in conditioned media from
either Tg or WT calvaria cell cultures (Supplementary Fig. 7d),
these results suggest that miR-125b secreted from osteoblasts is
mostly or all sequestered in the bone matrix via MVs.
Neither TRAP+ MNC formation (Fig. 3c) nor ability to resorb
bone in vitro (Supplementary Fig. 7e) was different between Tg and
WT BMM cell cultures. Similarly, and consistent with the view that
osteoblast-secreted miR-125b is undetectable in conditioned
medium but is sequestered in the bone matrix via MVs, osteoclast
formation was the same in Tg and WT BMMs cocultured with
either Tg or WT osteoblasts (calvaria cells forming osteoid-like
nodules) (Supplementary Fig. 7f). FACS analysis revealed that
CD117+/CD115+/CD11blow osteoclast progenitors28 (Fig. 3d),
macrophages, hematopoietic stem cells, and B cells were compar-
able between the two strains, with a small but substantial reduction
Fig. 1 MVs and miR-125b impair TRAP+ multinucleated cell (MNC) formation. To induce TRAP+ MNC formation, BMMs were cultured in the presence
of M-CSF alone or M-CSF plus RANKL (a–c). Cells were also treated with MVs (1 μg protein/mL) or PBS. a Representative images of TRAP+ MNCs (with
M-CSF and RANKL; scale bars, 100 µm) and the number of TRAP+ MNCs/well in the presence of MVs or PBS (n= 6). b Expression of osteoclast marker
genes (Nfatc1, Dcstamp, and Ctsk); Rpl32 was used as internal control (n= 3). c Representative images of resorption pits (scale bars, 50 μm) and pit areas
on dentin slices stained with hematoxylin (n= 6). d miRNA levels in MVs vs. their source MC3T3-E1 cells (n= 3). e miR-125b levels in human and rat
osteoblasts (hOb and rOb) and their MVs (hMV and rMV) (n= 3). Cells were cultured until osteoid-like nodules formed (d, e). To induce TRAP+ MNC
formation, RAW-D cells were treated with or without RANKL (f–i). f miR-125b and let-7c levels in MVs vs. RAW-D cells (n= 3). g miR-125b levels in
RAW-D cells treated with MVs or PBS, or transfected with miR-125b mimic (Mimic) or negative control miRNA (NC) (n= 3). U6 was used as internal
control (d–g). h Representative images of TRAP+ MNCs (scale bars, 100 µm) and the number of TRAP+ MNCs/well in the presence of Mimic or NC (n=
6). i Expression of osteoclast marker genes (Nfatc1, Dcstamp, and Ctsk) in RAW-D cells with Mimic or NC (n= 3); Rpl32 was used as internal control.
*, #P < 0.05, **, ##P < 0.01, and ***P < 0.001 vs. matched control by Tukey’s multiple comparison (a, b, f) and by Student’s t-test (c–e, g–i).
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in T cells in Tg mice in comparison with those in WT mice
(Supplementary Fig. 8). Taken together, these data suggest that
miR-125b trapped in bone matrix inhibits osteoclastogenesis.
Indeed, treatment of RWA-D cells with Tg MVs resulted in greater
inhibition of osteoclast formation than that with WT MVs (Fig. 3e).
When either Tg or WT BMMs were cultured on Tg vs. WT bones
in the presence of RANKL and M-CSF, TRAP+ spots were less on
Tg than WT bones (Fig. 3f). These results suggest that bone matrix
miR-125b decreases osteoclastogenesis.
We then searched public databases to identify putative
miR-125b target(s) (Supplementary Table 2). Of these, PR
domain containing 1, with zinc finger domain (PRDM1), a
transcriptional repressor of anti-osteoclastogenic factors16, was
selectively downregulated in RAW-D cells transfected with
miR-125b mimic (Supplementary Fig. 9) or treated with MVs
(Fig. 3g). Luciferase activity was reduced in RAW-D cells co-
transfected with miR-125b mimic and Prdm1 3′UTR reporter
vector, but not with miR-125b mimic and Prdm1 mutant 3′
Fig. 2 Transgenic (Tg) mice overexpressing miR-125b in osteoblasts exhibit a high bone mass phenotype. a Transgene construct. hOC, human
osteocalcin promoter; rβ-globin intron, rabbit β-globin intron. b miR-125b levels in various tissues and cells of 12-week-old male transgenic (Tg) and wild-
type (WT) mice; U6 was used as internal control (n= 3). c Microcomputed tomography (µCT) of 12-week-old male femurs (upper panels) and 10-week-
old female lumber vertebrae (L3, lower panels) (representative images of each phonotype; upper and lower panels indicate longitudinal and transverse
views, respectively). Scale bars, 1 mm (femurs) and 0.5 mm (L3). d Bone morphometric parameters of 12-week-old Tg and WT female distal femurs (WT,
n= 5; Tg, n= 7). Analysis was performed on the metaphyseal region with 7 μm width, based on the position 1 μm away from the distal femoral growth
plate. BV, bone volume (mm3); BMD, bone mineral density (mg/mm3); TV, tissue volume (mm3); Th, thickness (mm); Trabecular number (no./mm); Sep,
separation (mm). e–h Histology of 10-week-old Tg and WT female distal femurs (representative images in each genotype, n= 5). e ALPL-immunoreactive
cells delineate osteoblasts and the percentage of ALP+ cell surface per bone surface. Nuclear counterstaining with DAPI (scale bars, 25 µm). f Calcein
double-labeling (scale bars, 20 µm) and the corresponding mineral apposition rate (MAR) (n= 5). g, h TRAP+ multinuclear cells (MNCs) delineate
osteoclasts (scale bars, 50 μm) and the percentage of TRAP+ cell surface per bone surface. Left panel in g shows schematic image of the distal femur at
low magnification; cells within the square frames g and h were counted and plotted in g and h, respectively. Nuclear counterstaining with methyl green.
*P < 0.05, **P < 0.01, and ***P < 0.001 vs. WT by Student’s t-test.
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UTR reporter vector29 (Fig. 3h). Further, the miR-125b mimic
decreased levels of Prdm1 in RAW-D cells and concomitantly
increased mRNA (Fig. 3i) and protein (Supplementary Fig. 10)
levels of two known downstream targets of PRDM1 that are
inhibitors of osteoclastogenesis, interferon regulatory factor 8
(Irf8)30 and v-maf musculoaponeurotic fibrosarcoma oncogene
homolog B (Mafb)31, but not of a third potential inhibitor, B-
cell lymphoma 6 (Bcl6)16. The latter may reflect the fact that we
assessed at day 4 and may have missed later events in
osteoclastogenesis, as it is known that Bcl6 is downregulated
at a later stage of osteoclastogenesis (by 8 days)16 than either
Irf830 or Mafb31(by 24 h). Nevertheless, our results strongly
suggest that miR-125b suppresses osteoclast formation via
downregulation of PRDM1.
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miR-125b protects bone loss in mouse disease models. To
determine whether MV-based transfer of miR-125b to bone
matrix represents a potential therapeutic target, we ovar-
iectomized (OVX) 8-week-old female mice, as a model of post-
menopausal osteoporosis32. Four weeks post-OVX, body weight
was increased (Fig. 4a) and uteri were hypoplastic (Fig. 4b) in
both WT and Tg mice, indicating effective estrogen depletion.
However, OVX-induced trabecular bone loss was lower in Tg
compared to WT femora (Fig. 4c–e). Trabecular bone loss was
also markedly blunted in 10-week-old male Tg vs. WT mice
subjected to sciatic neurectomy (NX), a model of disuse or
immobilization-induced osteoporosis33 (Supplementary Fig. 11a,
b). Thus, overexpression of miR-125b in osteoblasts confers
resistance to bone loss in mouse osteoporosis models. Finally, to
confirm that miR-125b inhibits osteoclastogenesis in vivo, we
used subcutaneous injections of bacterial lipopolysaccharides
(LPSs) over the calvariae to increase osteoclastogenesis and
induce osteolysis30. Whole-mount staining showed that LPS-
induced TRAP staining was attenuated, when miR-125b mimic
was co-injected subcutaneously (Fig. 4f). These results indicate
that miR-125b can inhibit bone resorption in at least some
pathologic conditions. Taken together, our data identify miR-
125b accumulated in bone matrix as a player in bone metabolism
via osteoblast–osteoclast coupling and as a potential therapeutic
target to abrogate bone loss.
Discussion
MVs budding from osteoblasts are known to accumulate in
osteoid and play a crucial role in the initial steps of bone
mineralization9. However, potential but undefined roles of MVs
in bone metabolism have been postulated recently, based on
comprehensive analyses of proteins in MVs10,11. Together with
other recent findings of miRNAs as functional EV cargos1,2, these
prompted us to test for functional roles of MVs in bone. We
report here that miRNAs in osteoblasts are transported to bone
matrix by MVs. Of these, miR-125b is selectively and abundantly
incorporated into MVs and stored in bone matrix. During bone
resorption, miR-125b is released and targets PRDM1, a tran-
scriptional repressor of anti-osteoclastogenic factors16,17 in
osteoclast precursors. Tg mice overexpressing miR-125b in
osteoblasts exhibit increased miR-125b levels in MVs and bone
matrix, resulting in decreased osteoclast numbers and increased
bone mass. Overexpressing miR-125b in osteoblasts also abro-
gates the bone loss associated with estrogen deficiency and
immobilization in mice, consistent with the suppression of LPS-
induced osteoclast formation and osteolysis by injecting mice
with miR-125b mimic.
That osteoblasts secrete EVs and/or MVs with active biological
molecules as cargo is not in itself surprising. Indeed, a list of
numerous cargo proteins is available at http://bioinf.xmu.edu.cn/
MVsCarta/, but little is known about whether MV cargo mole-
cules accumulate in bone matrix, or have a substantial impact on
bone metabolism or turnover. Treatment of mouse BMMs with
EVs isolated from conditioned media of primary mouse osteo-
blast cultures has been shown to promote survival of osteoclasts
by the action of the cargo RANKL34. However, we found that
MVs do not mimic this effect, but rather inhibit formation of
osteoclasts and resorption pits, suggesting that anti-
osteoclastogenic factor(s) accumulate in MVs and are trans-
ported to bone matrix via MVs but not EVs. Recently, MVs
isolated from rat growth plate chondrocytes were reported to be
selectively enriched in certain miRNAs, including miR-122-5p,
miR-142-3p, miR-223-3p, and miR-451-5p12. We then focused
our attention on miRNAs as MV cargos. Interestingly, the
enrichment profile we identified in mouse, rat, and human
osteoblast MVs is distinctly different from that in rat chon-
drocytes12, suggesting that MVs from at least certain types of
chondrocytes exhibit a functionally distinct role, from
osteoblast MVs.
By in silico analyses, qRT-PCR screens, and selection of can-
didate miRNAs more abundant in osteoblasts and MVs than
osteoclasts or their precursor cells (BMMs and RAW-D cells), we
identified miR-125b for further study. We confirmed that the MV
cargo miR-125b regulates osteoclastogenesis but not osteo-
blastogenesis by gain- and loss-of function experiments in vitro.
While overexpression of miR-125b in osteoblasts clearly decreases
osteoclastogenesis, we found no evidence for miR-125b regulation
of osteoblast differentiation or bone formation in vivo. Of pre-
vious studies assessing miR-125b in osteoblast differentiation,
only two have reported a regulatory role for miR-125b in
osteogenesis, one with human bone marrow stromal cells, which
are from a multipotent stem cell-like population differentiated
under the influence of a medium whose constituents were
undisclosed or transplanted on demineralized bone matrix35, and
the other with ST2 stem-like cells in the presence of BMP-436. We
have found no detectable effect of miR-125b on the MC3T3-E1
model cultured under osteogenic conditions or ST2 cells under-
going osteogenesis in vitro in the absence of BMP-4. We also
found no effect on osteogenesis when we overexpressed miR-125b
in post-mitotic mature osteoblasts ex vivo and in vivo. It is not
surprising that miR-125b effects are different in different condi-
tions in vitro and in vivo, given the likelihood of extracellular
signal- and/or differentiation stage-specific miR-125b target gene
expression profiles in these different models. It is also possible
that the ability to detect effects of exogenously added miR-125b
on osteoblast development in vitro and ex vivo/in vivo are
abrogated by the already abundant expression of miR-125b in
these cells.
It is known that circulating miRNAs, whether within EVs or
not, are mostly associated with RNA-induced silencing complexes
Fig. 3 miR-125b in bone matrix inhibits osteoclastogenesis by targeting Prdm1. a Representative images of osteogenic activities in Tg and WT bone
marrow cell cultures, assessed by ALP/von Kossa staining (scale bars, 4.5 mm) and the percentage of ALP/von Kossa+ areas (n= 3). b miR-125b levels in
AGO2 immunoprecipitates from the cell and ECM fractions of WT vs. Tg bones (n= 3). c Representative images of TRAP+ multinucleated cells (MNCs) in
WT and Tg bone marrow macrophage (BMM) cultures stimulated with RANKL and M-CSF (scale bars, 100 µm) and the number of TRAP+ MNCs/well
(n= 6). d FACS analysis of Tg and WT osteoclast precursor (CD117+/CD115+/CD11blow) cells; cells were gated on CD117 (n= 8). e The number of TRAP+
MNCs/well in RAW-D cell cultures with or without WT MVs vs. Tg MVs (n= 6). Cells were stimulated with RANKL. f Representative images of TRAP
staining of either Tg or WT BMMs on Tg vs. WT calvarial bone chips (scale bars, 100 μm) and the percentage of TRAP+ areas (n= 4). αMEM shows bone
chips without BMMs. g Prdm1 levels in RAW-D cells with MVs (1 μg protein/mL) or PBS; Rpl32 was used as internal control (n= 3). h The reporter
constructs contained the miRNA response element (MRE) (Wild) of Prdm1 or its mutant, and reporter activities in RAW-D cells cotransfected with reporter
plasmids and miR-125b mimic (Mimic) (n= 4). i mRNA levels of Prdm1 and associated downstream target genes in RAW-D cells transfected with Mimic
and negative control miRNA (NC); Rpl32 was used as internal control (n= 3). BMMs and RAW-D cells were stimulated by RANKL plus M-CSF (c, f) and
RANKL (e, g–i), respectively. *P < 0.05, **, ##P < 0.01, and ***P < 0.001 vs. matched control by Student’s t-test (b, f, g, i) and by Tukey’s multiple
comparison (e, h).
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Fig. 4 miR-125b protects mice from pathological bone loss. a–e Eight-week-old Tg and WT female mice were either sham-operated or ovariectomized,
and analyzed 4 weeks later; values (a, b, d) are shown as percent changes of sham-operated mice (n= 5) vs. OVX mice (n= 7). a Body weights.
b Representative macroscopic images (scale bars, 1 mm) and wet weights of uteri. c Representative images of μCT analysis of femurs (scale bars, 1 mm).
d Bone morphometric analysis of trabecular bone in distal femurs. Parameters based on µCT analysis were estimated as described in Fig. 2 (d).
e Representative images of H&E staining of femurs (scale bars, 50 μm). f LPS-induced osteolysis with injections of miR-125b mimic (Mimic) or negative
control miRNA (NC) over the calvariae. Representative images of whole-mount TRAP staining (scale bars, 200 μm) and quantification of TRAP+ spots
(n= 6). *P < 0.05 and ***P < 0.001 vs. matched control by Student’s t-test (d) and by Tukey’s multiple comparison (f).
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(RISCs)37. The presence of miRNAs in various body fluids is now
well-established38, but we show that the biologically active miR-
125b within RISC accumulates and is retained in the extracellular
bone matrix. Of established genes involved in osteoclastogenesis,
we confirmed that Prdm1 is a target of miR-125b. PRDM1 was
originally isolated in human osteosarcoma cell lines39 and acts as
a transcriptional repressor. In addition to osteoclastogenesis16,17,
PRDM1 is involved in plasma cell fate determination40, and
forced expression of miR-125b decreases PRDM1 levels in the
human lymphoma cell line PC-K8 via its binding activity to
Prdm1 3′UTR41. Of identified targets of miR-125b, physiological
silencing of miR-125b is required in mouse granulocytic differ-
entiation42 and B-cell development43 in vitro via the targeting of
Jund and S1pr1, respectively. The other established target of miR-
125b, Lyn28, is involved in myeloid vs. B-cell fate determination
in mouse hematopoietic stem cell cultures44. However, FACS
analysis showed no significant differences in bone marrow cells
except for a small but substantial reduction in T cells in Tg vs.
WT mice. Together the data suggest that the accumulation of
MVs in bone matrix creates the conditions by which osteoblast-
derived miR-125b regulates osteoclastogenesis. During bone
mineralization, calcium phosphate crystals grow in and break
through MVs9, resulting in miR-125b capture in mineralizing
bone. As is true with other active proteins embedded in bone
matrix, e.g., TGF-β1 (ref. 45) during bone resorption, miR-125b
would be released allowing its anti-osteoclastogenic activity to be
manifest. This also predicts that there is a certain threshold of
bone resorption required to achieve levels of miR-125b for its
anti-osteoclastogenic effects.
Antiresorptive agents such as bisphosphonates and anti-
RANKL antibodies have been used for many years, especially in
the treatment of patients with osteoporosis and bone metastasis.
These agents block bone resorption, resulting in suppression of
bone turnover46,47. While the clinical benefits of anti-resorptive
agents are clear, reduced bone turnover can have deleterious
effects, e.g., medication-related osteonecrosis of the jaws, leading
to ongoing efforts to identify additional approaches to main-
taining and improving bone mass in a variety of conditions. It is
interesting that overexpression of miR-125b in osteoblasts has a
protective effect against both OVX- and NX-induced bone loss in
our Tg mice and miR-125b rescues LPS-dependent osteolysis.
Taken together, osteoblast–osteoclast communication via the MV
cargo miR-125b represents a potential therapeutic target for bone
loss (Fig. 5). As a corollary to this, future research directions must
also include more detailed dissection of physiological role(s) of
miR-125b in bone, as well as the mechanism(s) underlying
selective accumulation of miR-125b in MVs, retention of miR-
125b activity in mineralized bone overtime and delivery-uptake of
miR-125b by osteoclast precursors and possibly other cells (e.g.,
T-cells) in the bone microenvironment.
Methods
Animals. C57BL/6J and ddY mice and timed-pregnant Wistar rats were obtained
from CLEA Japan or Charles River Laboratories Japan. Tg mice overexpressing
miR-125b in osteoblasts were developed on the C57BL/6J background. Animal use
and procedures were approved by the Institutional Animal Care and Use Com-
mittee at the Central Institute for Experimental Animals and the Committee of
Animal Experimentation at Hiroshima University (#A14-078).
Vector construction. A 422-base-pair mouse genomic sequence including pre-
miRNA-125b-1 and rabbit βglobin intron and poly A were amplified by PCR from
mouse and rabbit genomic DNA, respectively, and cloned into pBlueScript II SK
(+) (miR-125b vector, UNITECH)48. A 4072-base-pair human osteocalcin pro-
moter27 was amplified from human BAC clone (RP11-964F7). The human
osteocalcin promoter fragment was inserted into the NotI/SpeI sites of the miR-
125b vector, and the 5690-base-pair NotI/SalI fragment was isolated, purified, and
used for microinjection. Tg mice were identified by PCR. Primer pairs are
described in Supplementary Table 3.
Microcomputed tomography (µCT). Bones were fixed in 4% paraformaldehyde
(PFA) in PBS at 4 °C overnight and stored in 70% ethanol. Samples were imaged
using Skyscan 1176 at an X-ray energy of 40 kV with a voxel size of 17.5 µm on
each side and an exposure time of 230 ms (Bruker microCT). Image reconstruction
and bone morphometry (proximal tibiae) were performed using NRecon and
CTvox software, respectively (Bruker microCT).
Calcein double-labeling and plastic sections. Calcein (100 µg/kg body weight)
was administered intraperitoneally twice (at a 6-day interval) to 10-week-old male
mice. Femurs were dissected 2 days after the second administration, fixed in 4%
PFA in PBS and embedded in Epon by standard techniques, and the MAR was
determined on plastic semi-thin sections studied under fluorescence microscopy49.
Histology. PFA-fixed bones were decalcified with 10% EDTA in PBS at 4 °C for a
week and embedded in paraffin by standard techniques. Deparaffinized sections (4
µm thick) were stained with TRAP to evaluate osteoclasts16–18. To determine
osteoblasts by ALP staining, sections were rinsed with Tris-buffered saline (20 mM
Tris-HCl, 137 mM NaCl; pH 7.6) containing 0.025% Triton X-100 and incubated
with Protein Block (Dako), followed by incubation with anti-ALPL antibody (×200,
Proteintech) in Can Get Signal® Solution A (Toyobo) at 4 °C overnight. Alexa
Fluor® 594-conjugated antibody (Thermo Fisher Scientific) was used as the sec-
ondary antibody. Fluoro-KEEPER with DAPI was used for nuclear staining.
Analysis of osteoclast progenitors. Bone marrow cells were prepared from
femurs and tibiae of 10-week-old male mice. Cells were passed through a cell
strainer (70 µm; Falcon®), centrifuged, and the resultant cell pellets were resus-
pended in ACK lysis buffer (0.15 M NH4Cl, 0.01M KHCO3, and 1 mM Na2 EDTA;
pH7.4) (hemolysis). After gentle agitation for 2 min, cell suspensions were cen-
trifuged and rinsed. Resuspended cells (4 × 105 cells in 100 μL of 0.5% BSA in PBS)
were treated with TruStain fcX for 5 min on ice, followed by incubation with
labeled antibodies or isotype controls for 60 min at 4 °C. Cells were then treated
with 1 mM EDTA and 2% BSA in PBS, centrifuged and resuspended with 0.5%
BSA in PBS. Osteoclast progenitors were determined by FACS (LSRFortessa X-20,
BD Biosciences) using CD115-Alexa Fluor 488, CD11b-APC, and CD117-PE
(BioLegend)28 (Supplementary Table 4).
Ovariectomy (OVX). Eight-week-old female mice were overiectomized or sham-
operated32, and samples were collected 4 weeks later.
LPS-induced osteolysis in vivo. LPS (Escherichia coli, 026:B65; Lot #025M4088V;
Sigma-Aldrich) was administered subcutaneously over the calvariae30 of 8-week-
old male ddY mice at days 0, 1, 3, and 5 (3.75 mg/kg/day). A miR-125b mimic or its
scrambled negative control (7 nmol each, Ambion) in AteloGene® (Koken) was
injected subcutaneously into the region close to the LPS-treated sites 12 h before
day 0 and at days 2 and 4. Calvariae were dissected at day 6 and fixed in 95%
ethanol and 5% acetic acid for whole-mount TRAP staining.
Cell cultures. MC3T3-E1 cells and ST2 cells were purchased from the RIKEN
BRC. Human osteoblastic cells were kindly provided by DV Biologics. Mouse and
rat calvaria cells were obtained from newborn C57BL/6 mice (around 3 days old)
and 21-day-old fetal Wistar rats, respectively50. Briefly, calvariae were aseptically
dissected and sequentially digested five times with type I collagenase (Sigma-
Aldrich) for 10–20 min. Cell fractions, except for the first one, were separately
cultured in α-MEM containing 10% FBS (Corning) and pooled the next day. We
also established the MC3T3-E1 cell subclone (E1low) that expresses miR-125b at
low levels by limiting dilution cloning51. To determine osteoblastogenesis, cells
were plated at 3000 cells/cm2 in the above medium additionally supplemented with
50 µg/mL ascorbic acid (osteogenic medium) with or without 10 mM β-
glycerophosphate (βGP) for 2–3 weeks. Cells were fixed with 4% PFA in PBS and
subjected to ALP and von Kossa staining. Image J 1.48 software (NIH) was used to
measure ALP- or ALP/von Kossa-positive (ALP+/von Kossa+) areas. ALP+/von
Kossa+ nodules were counted under a microscope.
Bone marrow cells from 9–12-week-old male mice were hemolyzed as above
and cultured at 500,000 cells/cm2 in non-adherent cell culture dishes with α-MEM
supplemented with 10% FBS and 100 ng/mL M-CSF (R&D Systems) for 2 days.
After removing non-adherent cells by washing with PBS, BMMs were collected
using Cellstripper™ (Corning), passaged one time, and replated at 8000–20,000
cells/cm2 and cultured with 50 ng/mL RANKL (Oriental Yeast) and 50 ng/mL M-
CSF for 4–5 days16,18. RAW-D cells were plated at 2000 cells/cm2 in the presence
or absence of 50 or 100 ng/mL RANKL for 4 days20. TRAP-positive multinuclear
cells (TRAP+ MNCs; five nuclei or more) were regarded as osteoclasts. In some
resorption assays, Tg and WT BMMs (9500 cells/cm2) were cultured on calvarial
bone chips (6 mm × 6mm) for 6 days, followed by fixation with 4% PFA in PBS,
TRAP staining, and Image J analysis. Calvarial bone chips were collected from
either Tg or WT newborn mice and preserved in ice-cold methanol for a few days
at −20 °C. All cells were cultured at 37 °C in a humidified atmosphere with 5% CO2
with medium changes every second or third day, unless otherwise specified.
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Resorption pit formation assay. BMMs at 100,000–280,000 cells on dentin slices
(Wako) or bovine cortical bone slices were grown in α-MEM supplemented with
10% FCS, with 50 ng/mL M-CSF and 50 ng/mL RANKL up to 7–14 days. Dentin/
bone slices were rinsed with ammonia water, stained with hematoxylin or toluidine
blue21 and resorption pit areas measured by Image J.
Isolation of MVs. MVs were isolated from the ECM deposited by osteoblasts52.
Briefly, MC3T3-E1 cells, primary calvaria cells, and human osteoblastic cells were
grown at 3000 cells/cm2 in osteogenic medium. To confirm the formation of bone-
like nodules, βGP was added to parallel cultures. When the ECM (osteoid-like
nodules) formed (−3 weeks), cultures without βGP were treated with 500 units/mL
collagenase (Sigma-Aldrich) at 37 °C for 45 min under static conditions and for 15
min with shaking. Samples were then centrifuged at 20,000 × g for 20 min, and
pellets were subjected to protein and total RNA extraction as cell extracts.
Supernatants were centrifuged at 100,000 × g for 60 min, and the resultant pellets
were resuspended in 100 mM mannitol in 10 mM HEPES (pH 7.5), followed by
centrifugation at 350,000 × g for 30 min. Finally, MV pellets were resuspended in
PBS and aliquots (2 μg protein/μL stock solution) were stored in liquid nitrogen
until use. Two micrograms of protein/mL or less of MVs were used for bioassays.
BCA protein assay. Protein levels in lysates of MVs or cells (Cell-LyEX MP,
TOYO B-Net) including phosphatase inhibitors) were determined using colori-
metric detection according to the manufacturer’s instructions (Pierce™ BCA protein
assay kit, Thermo Fisher Scientific).
Comprehensive analysis of miRNAs in MVs. miRNAs in MVs from MC3T3-E1
cells were extracted three times independently using a mirVana™ miRNA isolation
kit, according to the manufacturer’s instructions (Ambion). Probe labeling (using
100 ng of total RNA) and hybridization were performed using a miRNA Complete
Labeling and Hyb kit and a SurePrint G3 mouse miRNA microarray rel.17 kit,
respectively (Agilent Technologies). miRNA profiling for three MVs was analyzed
using an Agilent G2539A microarray scanner and analysis software GeneSpring
GX (version 12.5.0, Agilent Technologies). Of miRNAs identified, we focused on
those common to humans and mice, and predicted targets were searched using
public databases (miRTarBase: http://mirtarbase.mbc.nctu.edu.tw; miRDB: http://
mirdb.org/miRDB/; RNA22: https://cm.jefferson.edu/rna22v2/; and TargetScan-
Human 6.2: http://www.targetscan.org/).
AGO2 immunoprecipitation of bones. The osteocyte isolation method53 with
slight modification was used to obtain miRNAs from bone matrices. Briefly, cal-
variae from 8–15-week-old male C57BL/6 mice were cut into small pieces (2 × 2
mm), washed, and digested with 300 U/mL collagenase (type I, Sigma-Aldrich) in
isolation buffer (70 mM NaCl, 10 mM NaHCO3, 60 mM sorbitol, 30 mM KCl, 3
mM K2HPO4, 1 mM CaCl2, 1 mg/mL BSA, and 5 mg/mL glucose in 25 mM
HEPES; pH7.4) at 37 °C for 20 min with shaking. Undigested bone pieces were
then stirred two times with 10% EDTA in PBS at 37 °C for 20 min and 30 min. All
digestion fractions were divided into cell pellets and bone matrix extracts by
centrifugation. miRNAs were trapped by antibodies against AGO2 as part of the
RISC37. Aliquots of cell pellets lysed with lysis buffer and bone matrix extracts were
incubated with anti-AGO2 mouse antibody-conjugated magnetic beads at 4 °C
overnight according to the manufacturer’s instructions (MagCapture miRNA kit,
Wako). Mouse IgG (Santa Cruz Biotechnology)-conjugated Dynabeads Protein G
(Life Technologies) were used as control. After washing, immunoprecipitates with
magnetic beads were eluted and processed for RNA extraction according to the
manufacturer’s instructions.
miR-125b mimic transfection. RAW-D cells at 2000–3000 cells/cm2 were grown
overnight and transfected with miR-125b mimic or its scrambled negative control
(10 nM each) using RNAiMAX reagent (Life Technologies) or HiperFect Trans-
fection Reagent (Qiagen), according to the manufacturers’ instructions. After 3 h, a
small amount of fresh medium including RANKL (final 50 ng/mL) was added to
cultures, and cells were maintained for an additional few days.
Prdm1 3ʹUTR luciferase reporter vector and luciferase assay. The 3′UTR of
Prdm1 (2693-3145 in NCBI accession #: NM_007548.3) was amplified from
genomic DNA of RAW-D cells. The amplified 3′UTR was cloned into the SpeI and
HindIII sites of pMIR-REPORT (Invitrogen). The mutant 3′UTR29 was generated
using primer sets and cloned as described above. Primer sets are shown in Sup-
plementary Table 3. RAW-D cells were grown at 25,000 cells/cm2 overnight and
then co-transfected with reporter plasmid (80 ng) and pGL44.74[hRluc/TK] vector
(40 ng; Promega; Madison, WI) using Attractene Transfection Reagent (Qiagen),
according to the manufacturer’s instructions. Twenty-four hours later, miR-125b
mimic or negative control (10 nM each, Ambion) was introduced into cells as
described above. Cells were maintained for an additional 36 h and then lysed in
passive lysis buffer (Promega). Measurements were performed using the Dual-
luciferase® reporter assay system (Promega).
PCR analysis. Genomic DNA was extracted and the transgene was determined
using KOD FX Neo (Toyobo) with specific primer sets. miRNAs in conditioned
media were isolated by using a miRNeasy Serum/Plasma Advanced kit (Qiagen).
Total RNA was isolated from cells using TriPure isolation reagent (Roche Diag-
nostics), and reverse-transcribed using ReverTra Ace® (Toyobo). For miRNAs,
TaqMan® microRNA assays (Applied Biosystems), and their corresponding primer
sets, including U6 (cells and MVs) and miR-16 (bone matrix) as internal controls,
were used according to the manufacturers’ instructions. For mRNAs, Rpl32 served
as internal control, and qPCR amplification was conducted using Fast SYBR® green
master mix (Applied Biosystems). The sequences of primer sets are shown in
Supplementary Table 3.
Fig. 5 Schematic diagram of osteoblast–osteoclast communication by miR-125b. Osteoblasts secrete matrix vesicles (MVs), including their cargo miR-
125b, which accumulate in unmineralized bone matrix (osteoid). Through calcium phosphate crystal growth and MV membrane disruption, miR-125b is
trapped in mineralized bone. miR-125b is taken up by osteoclast precursors such as during osteoclastic bone resorption. miR-125b in osteoclast precursors
binds to Prdm1 mRNA to decrease Prdm1 protein level, resulting in increased anti-osteoclastogenesis factors, such as IRF8 and MAFB, and thereby
decreased osteoclast formation and associated bone resorption.
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Statistics and reproducibility. Data are expressed as mean ± SD. Non-numerical
data are shown as representative results of three independent experiments. Sta-
tistical differences were evaluated using either one-way or two-way analysis of
variance (ANOVA), followed by Tukey’s multiple comparison (multiple groups) or
Student’s t-test (two groups). A P-value < 0.05 was considered statistically
significant.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The majority of the data supporting the findings of this study are included in this
published article. Additionally, raw data are available from the corresponding author on
reasonable request. The source data underlying plots are presented in Supplementary
Data 1. The miRNA microarray data are deposited into NCBI GEO (accession number:
GSE140242). miRNAs identified in MVs are shown in Supplementary Data 2.
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